Physician profile
Emily Whitty
NPI 1215700893
$2,379.54
in general payments reported to CMS, 2019-2025
29 companies · $798 in 2025
The $798 reported for 2025 was more than what 83% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,582 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $314.03 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $276.76 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $258.44 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $186.28 | 2024-2025 | |
| Abbvie INC. | $177.86 | 2024-2025 | |
| Dexcom, INC. | $162.42 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $133.11 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $126.32 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.33 | 2024-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $106.38 | 2024-2025 | Spravato, Xarelto |
| E.R. Squibb & Sons, L.L.C. | $98.50 | 2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.13 | 2024-2025 | Jardiance, Synjardy |
| Exact Sciences Corporation | $34.37 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $32.00 | 2024 | Verquvo |
| Corcept Therapeutics | $29.36 | 2025 | Korlym |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24.81 | 2024 | Arexvy, Shingrix |
| Philips North America LLC | $23.05 | 2024 | (5091) Amb Mon & Diag Und |
| Paratek Pharmaceuticals, INC. | $22.73 | 2024 | Nuzyra |
| Insulet Corporation | $22.33 | 2024 | Omnipod |
| Alexion Pharmaceuticals, INC. | $22.29 | 2025 | Strensiq |
| Medtronic, INC. | $22.15 | 2025 | Minimed 780g |
| Sequel Med Tech, LLC | $21.81 | 2025 | Twiist |
| Hologic Sales and Service, LLC | $21.65 | 2025 | Aptima |
| Sumitomo Pharma America, INC. | $18.11 | 2025 | Gemtesa |
| Verona Pharma, INC. | $17.13 | 2025 | Ohtuvayre |
| Amgen INC. | $15.22 | 2025 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.85 | 2025 | Caplyta |
| Lundbeck LLC | $14.39 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $13.73 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Whitty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.